ACCURAY INCORPORATED SUNNYVALE, Calif., April 27, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third fiscal quarter and nine months ended March 31, 2017.
Fiscal Third Quarter Highlights
-- Ending backlog increased 21 percent year-over-year to $450.0 million;
gross orders increased 49 percent to $83.8 million; net orders were
$71.8 million
-- Gross orders featured a strong contribution from CyberKnife® Systems of
which approximately two-thirds were equipped with the InCise(TM)
Multileaf Collimator ("MLC")
-- Japanese regulatory approval received to market the recently launched
Radixact(TM )System
-- Radixact ramp and monitor sites concluded; full commercial launch
underway
-- Additional study data presented at ASCO GU demonstrated the clinical
efficacy of the CyberKnife® System with 100 percent of low-risk and
88.5 percent of intermediate-risk prostate cancer patients having
excellent cancer control five years after receiving treatment ((1))
"Our 49% year-over-year gross order growth during the third quarter was led by increased demand for our CyberKnife System especially from existing customers," said Joshua H. Levine, president and chief executive officer. "In addition, gross orders were favorably impacted by solid demand for our new Radixact System, which is now in full commercial launch. The third quarter gross orders have resulted in nine-month order results that are above expectations. We are seeing several indicators that lead us to believe our strong order growth will continue through the end of fiscal 2017 and into fiscal 2018."
Financial Highlights
Gross product orders totaled $83.8 million for the 2017 fiscal third quarter compared to $56.4 million for the prior fiscal year period. Ending product backlog was $450.0 million, approximately 21 percent higher than backlog at the end of the prior fiscal year third quarter.
Total revenue was $97.3 million compared to $105.3 million in the prior fiscal year third quarter. Service revenue totaled $49.3 million compared to $51.5 million, while product revenue totaled $48.0 million compared to $53.7 million in the prior fiscal year third quarter. The decrease in product revenue was primarily due to slower conversion of backlog to revenue from system orders placed by international distributors as well as continued delays in the awarding of Class A licenses by the government of China. Service revenue declined as a result of lower installation and training revenue linked to the lower product revenue as well as declines in spare parts sales.
"Our revenue performance from the quarter was below expectation, largely due to the extended conversion from backlog to revenue we have experienced during the past two quarters from orders placed through international distributors," said Mr. Levine. "We are strengthening the alignment and coordination of support activities with our independent distribution partners which will improve our revenue conversion timelines. Our confidence in the conversion of our orders remains high and we expect to begin to see some results from our focused efforts as we move into fiscal 2018. While we are reiterating our gross order outlook for the year, we are modifying our revenue outlook."
Total gross profit for the 2017 fiscal third quarter was $35.4 million or 36 percent of sales, comprised of product gross margin of 38 percent and service gross margin of 34 percent. This compares to total gross profit of $44.9 million or 43 percent of sales, comprised of product gross margin of 45 percent and service gross margin of 40 percent for the prior fiscal year third quarter. The decrease in gross margin stemmed from lower sales unit volume as well as product and channel mix.
Operating expenses were $36.7 million, a decrease of 7 percent compared with $39.5 million in the prior fiscal third quarter. The decrease was primarily because of lower legal fees and research and development expenses.
Net loss was $5.0 million, or $0.06 per share, for the third quarter of fiscal 2017, compared to a net income of $0.8 million, or $0.01 per share, for the third quarter of fiscal 2016.
Adjusted EBITDA for the third quarter of fiscal 2017 was $7.1 million, compared to $13.9 million in the prior fiscal year third quarter.
Cash, cash equivalents and investments were $84.1 million as of March 31, 2017, a decrease of $24.3 million from December 31, 2016, primarily due to working capital usage and restricting cash of $12.5 million to satisfy future payment obligations associated with the Company's secured term loan.
Nine Month Highlights
For the nine months ended March 31, 2017, gross product orders totaled $212.6 million compared to $188.4 million for the same prior year period.
Total revenue for the nine months ended March 31, 2017, was $271.3 million compared to $303.8 million in the prior fiscal year period. Service revenue totaled $152.3 million compared to $154.3 million from the prior fiscal year period, while product revenue totaled $119.0 million compared to $149.5 million in the prior year period. The decrease in revenue is the result of extended revenue conversion times mainly resulting from a higher percentage of order growth in the Company's distributor channels, which results in less direct control over the timing of revenue.
Total gross profit for the nine months ended March 31, 2017, was $98.2 million or 36 percent of sales, comprised of product gross margin of 36 percent and service gross margin of 36 percent. This compares to total gross profit of $121.4 million or 40 percent of sales, comprised of product gross margin of 43 percent and service gross margin of 37 percent for the same prior fiscal year period. The decrease in gross margin stemmed from lower sales unit volume as well as product and channel mix.
Operating expenses were $110.8 million, a decrease of 10 percent compared with $123.3 million in the prior fiscal year period. The decrease was primarily because of lower legal fees and research and development expenses.
Net loss was $24.3 million, or $0.30 per share, for the nine months ended March 31, 2017, compared to a net loss of $18.3 million, or $0.23 per share, for the prior year fiscal period.
Adjusted EBITDA for the nine months ended March 31, 2017 was $10.1 million, compared to $19.6 million in the prior fiscal year period.
Cash, cash equivalents and investments were $84.1 million as of March 31, 2017, a decrease of $82.9 million from June 30, 2016. This decrease was the result of using $36.6 million to fully repay the Company's 3.75 percent convertible debt in August 2016, $7.6 million in secured debt principal pay down, restricting cash of $12.5 million to satisfy future payment obligations associated with the Company's secured term loan and working capital usage.
2017 Financial Guidance
The Company is updating its guidance originally provided on August 17, 2016 as follows:
-- The outlook for Gross Orders growth of approximately five percent is
reaffirmed
-- Revenue for the fiscal year is now expected to range between $380.0
million and $390.0 million versus prior guidance of $410.0 million to
$420.0 million
-- Operating Expenses are now expected to be 8 to 10 percent less than
fiscal 2016, better than prior guidance of a 3 to 4 percent decrease
over prior year, primarily due to less incentive compensation expense
due to the lower revenues
-- Adjusted EBITDA is now expected to range between $22.0 million and $26.0
million as compared to prior guidance of $32.0 million to $38.0 million
Conference Call Information
Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss its fiscal third quarter results and recent corporate developments. Conference call dial-in information is as follows:
-- U.S. callers: (855) 867-4103
-- International callers: (262) 912-4764
-- Conference ID Number (U.S. and international): 8374292
Individuals interested in listening to the live conference call via the Internet may do so by logging on to Accuray's website, www.accuray.com. In addition, a taped replay of the conference call will be available beginning approximately two hours after the call's conclusion and available for seven days. The replay telephone number is (855) 859-2056 (USA) or (404) 537-3406 (International), Conference ID: 8374292. An archived webcast will also be available at Accuray's website.
Use of Non-GAAP Financial Measures
Accuray has supplemented its GAAP net loss with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization and stock-based compensation ("adjusted EBITDA"). Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net loss (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedule below.
Accuray presents certain measures, such as period-over-period revenue growth, on a constant currency basis, which excludes the effects of foreign currency translation. Due to the continuing strengthening of the U.S. dollar against foreign currencies and the overall variability of foreign exchange rates from period to period, management uses these measures on a constant currency basis to evaluate period-over-period operating performance. Measures presented on a constant currency basis are calculated by translating current period results at prior period monthly average exchange rates.
There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations, including management's expectations regarding orders, backlog, operating expenses, revenues and adjusted EBITDA, ability to meet financial targets, ability to influence revenue conversion, and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to: the company's ability to convert backlog to revenue; the timing of the China Class A license announcement, the success of the adoption of our CyberKnife, TomoTherapy and Radixact Systems; the company's ability to manage its expenses; continuing uncertainty in the global economic environment; and other risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, which was filed on August 24, 2016, the company's reports on Form 10-Q, which were filed on November 1, 2016 and February 3, 2017, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
(1) Fuller et al. 5-year outcomes from a
prospective multi-institutional
trial of heterogeneous dosing
stereotactic body radiotherapy
(SBRT) for low- and intermediate-
risk prostate cancer. J Clin Oncol
35, 2017 (suppl 6S; abstract 35);
abstract 35
Financial Tables to Follow
Accuray Incorporated
Consolidated Statements of Operations
(in thousands, except per share data)
(Unaudited)
Three Months Ended Nine Months Ended
March 31, March 31,
--------- ---------
2017 2016 2017 2016
---- ---- ---- ----
Gross Orders $83,823 $56,410 $212,612 $188,416
Net Orders 71,830 57,559 163,086 145,037
Order Backlog 449,955 370,488 449,955 370,488
Net revenue:
Products $48,032 $53,740 $119,029 $149,494
Services 49,280 51,544 152,291 154,333
------
Total net revenue 97,312 105,284 271,320 303,827
Cost of revenue:
Cost of products 29,574 29,622 75,895 85,356
Cost of services 32,313 30,718 97,269 97,058
Total cost of
revenue 61,887 60,340 173,164 182,414
------ ------ ------- -------
Gross profit 35,425 44,944 98,156 121,413
Operating expenses:
Research and
development 12,484 13,270 36,657 42,497
Selling and
marketing 13,025 12,516 41,247 41,009
General and
administrative 11,184 13,716 32,890 39,820
Total operating
expenses 36,693 39,502 110,794 123,326
------ ------ ------- -------
Income (loss) from
operations (1,268) 5,442 (12,638) (1,913)
Other expense, net (2,919) (3,963) (11,044) (14,124)
Income (loss) before
provision for
income taxes (4,187) 1,479 (23,682) (16,037)
Provision for income
taxes 842 723 642 2,260
--- ---
Net income (loss) $(5,029) $756 $(24,324) $(18,297)
======= ==== ======== ========
Net income (loss)
per share -basic $(0.06) $0.01 $(0.30) $(0.23)
====== ===== ====== ======
Net income (loss)
per share -diluted $(0.06) $0.01 $(0.30) $(0.23)
====== ===== ====== ======
Weighted average common shares used in
computing income (loss) per share:
Basic 82,913 80,860 82,268 80,320
====== ====== ====== ======
Diluted 82,913 82,071 82,268 80,320
====== ====== ====== ======
Accuray Incorporated
Consolidated Balance Sheets
(in thousands)
(Unaudited)
March 31, June 30,
2017 2016
---- ----
Assets
Current assets:
Cash and cash equivalents $60,170 $119,771
Investments 23,906 47,239
Restricted cash 1,154 891
Accounts receivable, net 87,091 56,810
Inventories 116,573 115,987
Prepaid expenses and other current assets 17,704 16,098
Deferred cost of revenue 3,725 4,884
Total current assets 310,323 361,680
Property and equipment, net 23,353 27,878
Goodwill 57,742 57,848
Intangible assets, net 1,646 7,611
Deferred cost of revenue 666 1,996
Other assets 23,117 12,020
Total assets $416,847 $469,033
========
Liabilities and equity
Current liabilities:
Accounts payable $23,633 $15,229
Accrued compensation 24,224 18,725
Other accrued liabilities 18,551 22,184
Short-term debt 115,702 39,900
Customer advances 18,853 22,123
Deferred revenue 95,250 92,051
Total current liabilities 296,213 210,212
Long-term liabilities:
Long-term other liabilities 10,542 10,984
Deferred revenue 10,301 17,665
Long-term debt 54,335 170,512
Total liabilities 371,391 409,373
Equity:
Common stock 83 81
Additional paid-in capital 492,311 481,346
Accumulated other comprehensive loss (1,807) (960)
Accumulated deficit (445,131) (420,807)
Total equity 45,456 59,660
------
Total liabilities and equity $416,847 $469,033
========
Accuray Incorporated
Reconciliation of GAAP Net Loss to Adjusted Earnings Before Interest, Taxes, Depreciation,
Amortization and Stock-Based Compensation (Adjusted EBITDA)
(in thousands)
(Unaudited)
Three Months Ended Nine Months Ended
March 31, March 31,
--------- ---------
2017 2016 2017 2016
---- ---- ---- ----
GAAP net income (loss) $(5,029) $756 $(24,324) $(18,297)
Amortization of intangibles (a) 1,988 1,988 5,965 5,964
Depreciation (b) 2,580 2,594 7,883 7,679
Stock-based compensation (c) 3,598 3,566 9,985 9,445
Interest expense, net (d) 3,138 4,291 9,902 12,585
Provision for income taxes 842 723 642 2,260
Adjusted EBITDA $7,117 $13,918 $10,053 $19,636
====== ======= ======= =======
(a) consists of amortization of
intangibles -developed
technology.
(b) consists of depreciation,
primarily on property and
equipment.
(c) consists of stock-based
compensation in accordance with
ASC 718.
(d) consists primarily of interest
income from available-for-sale
securities and interest expense
associated with our convertible
notes and term loan.
Accuray Incorporated
Forward-Looking Guidance
Reconciliation of Projected Net Loss to Projected Adjusted Earnings Before Interest, Taxes, Depreciation,
Amortization and Stock-Based Compensation (Adjusted EBITDA)
(in thousands)
(Unaudited)
Twelve Months Ending June
30, 2017
--------
From To
---- ---
GAAP net loss $(24,575) $(20,575)
Amortization of intangibles (a) 7,650 7,650
Depreciation (b) 10,325 10,325
Stock-based compensation (c) 13,100 13,100
Interest expense, net (d) 13,500 13,500
Provision for income taxes 2,000 2,000
Adjusted EBITDA $22,000 $26,000
======= =======
(a) consists of amortization of
intangibles -developed
technology.
(b) consists of depreciation,
primarily on property and
equipment.
(c) consists of stock-based
compensation in accordance with
ASC 718.
(d) consists primarily of interest
income from available-for-sale
securities and interest expense
associated with our convertible
notes and tem loan.
Doug Sherk Beth Kaplan
Investor Relations, EVC Group Public Relations Director, Accuray
+1 (415) 652-9100 +1 (408) 789-4426
dsherk@evcgroup.com bkaplan@accuray.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/accuray-third-quarter-gross-orders-increase-49-yoy-backlog-up-21-300447564.html
SOURCE Accuray Incorporated
